\addvspace {10\p@ }
\addvspace {10\p@ }
\contentsline {figure}{\numberline {2.1}{\ignorespaces BDS report showing pipelineâ€™s task execution timeline}}{93}
\contentsline {figure}{\numberline {2.2}{\ignorespaces Execution example \texttt {pipeline.bds}}}{94}
\contentsline {figure}{\numberline {2.3}{\ignorespaces Whole-genome sequencing analysis pipeline's flow chart}}{96}
\contentsline {figure}{\numberline {2.4}{\ignorespaces Architecture independence example}}{97}
\contentsline {figure}{\numberline {2.5}{\ignorespaces Scaling dataset sized by a factor of \nobreakspace {}1000}}{98}
\addvspace {10\p@ }
\contentsline {figure}{\numberline {3.1}{\ignorespaces Output of SnpEff.}}{103}
\contentsline {figure}{\numberline {3.2}{\ignorespaces Detailed effect list from SnpEff}}{106}
\contentsline {figure}{\numberline {3.3}{\ignorespaces Information provided by SnpEff in tab separated output format (TXT)}}{108}
\contentsline {figure}{\numberline {3.4}{\ignorespaces Information provided by SnpEff in variant call format (VCF)}}{111}
\contentsline {figure}{\numberline {3.5}{\ignorespaces Classification of SNPs in $w^{1118} ; iso-2; iso-3$}}{112}
\contentsline {figure}{\numberline {3.6}{\ignorespaces 60 Genes with start-gaineded SNPs with ATGs}}{113}
\contentsline {figure}{\numberline {3.7}{\ignorespaces Genes with start-gained SNP GO categories in $w^{1118} ; iso-2; iso-3$}}{113}
\contentsline {figure}{\numberline {3.8}{\ignorespaces Analysis of Eip63E start-gained SNP in $w^{1118} ; iso-2; iso-3$}}{115}
\contentsline {figure}{\numberline {3.9}{\ignorespaces Stop gained and stop lost in $w^{1118} ; iso-2; iso-3$}}{116}
\contentsline {figure}{\numberline {3.10}{\ignorespaces Oc/Otd has two stop-gained SNPs in $w^{1118} ; iso-2; iso-3$}}{117}
\contentsline {figure}{\numberline {3.11}{\ignorespaces CG34326 has one stop-gained SNP in $w^{1118} ; iso-2; iso-3$ in the non-conserved C-terminal region.}}{120}
\contentsline {figure}{\numberline {3.12}{\ignorespaces Nonsynonymous to synonymous ratios along the chromosome arms in $w^{1118} ; iso-2; iso-3$}}{122}
\contentsline {figure}{\numberline {3.13}{\ignorespaces CG13958 has a stop lost SNP in $w^{1118} ; iso-2; iso-3$}}{125}
\addvspace {10\p@ }
\contentsline {figure}{\numberline {4.1}{\ignorespaces Analysis pipeline schematic}}{135}
\contentsline {figure}{\numberline {4.2}{\ignorespaces Histogram of log-likelihood values of pairs of amino acids in contact vs not in contact (within protein).}}{146}
\contentsline {figure}{\numberline {4.3}{\ignorespaces Classifier's receiver operator curve (ROC)}}{147}
\contentsline {figure}{\numberline {4.4}{\ignorespaces Histogram of log-likelihood values of pairs of amino acids in contact vs not in contact (co-crystallized proteins)}}{148}
\contentsline {figure}{\numberline {4.5}{\ignorespaces Example of amino acid interaction}}{150}
\contentsline {figure}{\numberline {4.6}{\ignorespaces Results from epistatic GWAS analysis of type II diabetes sequencing data}}{152}
\contentsline {figure}{\numberline {4.7}{\ignorespaces Power calculation using a pure two-loci epistatic model}}{154}
\contentsline {figure}{\numberline {4.8}{\ignorespaces Distribution of $\ell _C$ for interacting genes and non-interacting genes}}{161}
\contentsline {figure}{\numberline {4.9}{\ignorespaces Distribution of $\ell _C$ across different clinical categories from ClinVar database}}{162}
\addvspace {10\p@ }
